Challenge of chimpanzees immunized with a recombinant canarypox-HIV-1 virus

Virology

Volumn 232, Issue 1, 1997, Pages 98-104

  Girard, Marc ^a   Van Der Ryst, Elna ^a,g   Barré Sinoussi, Françoise ^a   Nara, Peter ^b   Tartaglia, James ^c   Paoletti, Enzo ^c   Blondeau, Christine ^d   Jennings, Myra ^e   Verrier, Florence ^a   Meignier, Bernard ^d   Fultz, Patricia N ^f  

^a INSTITUT PASTEUR   (France)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Virogenetics Corporation   (United States)

^d Pasteur Merieux Connaught   (France)

^e NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF THE FREE STATE   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CHIMPANZEE; DRUG EFFICACY; DRUG SCREENING; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; NONHUMAN; POXVIRUS; PRIORITY JOURNAL;

EID: 17144470320     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1997.8560     Document Type: Article

References (39)

1. Arthur L. O., Bess J. W., Waters D. J., Pyle S. W., Kelliher J. C., Nara P. L., Krohn K., Robey W. G., Langlois A. J., Gallo R. C., Fischinger P. J. Challenge of chimpanzees (Pan troglodytes. J. Virol. 63:1989;5046-5053.
2. Baxby D., Paoletti E. Potential use of non-replicating vectors as recombinant vaccines. Vaccine. 10:1992;8-9.
3. Berman P. W., Gregory T. J., Riddle L., Nakamura G. R., Champe M. A., Porter J. P., Wurm F. M., Hershberg R. D., Cobb E. K., Eichberg J. W. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature. 345:1990;622-625.
4. Berman P. W., Murphy K. K., Wrin T., Vennari J. C., Cobb E. K., Eastman D. J., Champe M., Nakamura G. R., Davison D., Powell M. F., Bussiere J., Francis D. P., Matthews T., Gregory T. J., Obijeski J. F. Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1. J. Infect. Dis. 173:1996;52-59.
5. Bou-Habib D. C., Roderiquez G., Oravecz T., Berman P. W., Lusso P., Norcross M. A. Cryptic nature of envelope V3 region epitope protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J. Virol. 68:1994;6006-6013.
6. Bruck C., Thiriart C., Fabry L., Francotte M., Pala P., van Opstal O., Culp J., Rosenberg M., de Wilde M., Heidt P., Heeney J. HIV-1 envelope-elicited neutralizing antibody titers correlate with protection and virus load in chimpanzees. Vaccine. 12:1994;1141-1148.
7. Cadoz M., Strady A., Meignier B., Taylor J., Tartaglia J., Paoletti E., Plotkin S. Immunization with canarypox virus expressing rabies glycoprotein. Lancet. 339:1992;1429-1432.
8. Clements J. E., Montelaro C., Zink M. C., Amedee A. M., Miller S., Trichel A. M., Jagerski B., Hauer D., Martin L. N., Bohm R. P., Murphey-Corb M. Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus. J. Virol. 69:1995;2737-2744.
9. Daar E. S., Li X. L., Moudgil T., Ho D. D. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc. Natl. Acad. Sci. USA. 87:1990;6574-6578.
10. Devash Y., Calvelli T., Wood D., Reagan K., Rubinstein A. Vertical transmission of HIV-1 is correlated with the absence of high affinity/avidity maternal antibodies to the gp120 principal neutralizing domain. Proc. Natl. Acad. Sci. USA. 87:1990;3445-3449.
11. Erickson A. L., Houghton M., Choo Q. L., Weiner A. J., Ralston R., Muchmore E., Walker C. M. Hepatitis C virus-specific CTL responses in the liver of chimpanzees with acute and chronic hepatitis C. J. Immunol. 151:1993;4189-4199.
12. Farrar G. H., Roff M. A., Amin T., Ball J., Parret A. M., Battacharayya U., Booth J., Wansbrough-Jones M. H., Greenaway P. J. Characterization of a series of human immunodeficiency virus isolates derived sequentially from a single patient. J. Med. Virol. 34:1991;104-113.
13. Fultz P. N., McClure H. M., Swenson R. B., McGrath C. R., Brodie A., Getchell J., Jensen F. C., Anderson D. C., Broderson J. R., Francis D. P. Persistent infection of chimpanzees with human T-lymphotropic virus type III/lymphadenopathy-associated virus: A potential model for acquired immunodeficiency syndrome. J. Virol. 58:1986;116-124.
14. Fultz P. N., Srinivasan A., Greene C. R., Butler D., Swenson R. B., McClure H. M. Superinfection of a chimpanzee with a second strain of human immunodeficiency virus. J. Virol. 61:1987;4026-4029.
15. Fultz P. N., Nara P., Barré-Sinoussi F., Chaput A., Greenberg M. L., Muchmore E., Kieny M. P., Girard M. Vaccine protection of chimpanzees against challenge with HIV-1 infected peripheral blood mononuclear cells. Science. 256:1992;1687-1690.
16. Fultz P. N. Superinfection of chimpanzees with HIV-1 strains representing the same or different subtypes. Retroviruses of Human AIDS and Related Animal Diseases; Dixieme Colloque des Cent Gardes. 1995;Elsevier, Paris. p. 173-177.
17. Girard M., Kieny M. P., Pinter A., Barré-Sinoussi F., Nara P., Kolbe H., Kusumi K., Chaput A., Reinhardt T., Muchmore E., Ronco J., Kaczorek M., Gomard E., Gluckman J. C., Fultz P. N. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc. Natl. Acad. Sci. USA. 88:1991;542-546.
18. Girard M., Meignier B., Barré-Sinoussi F., Kieny M. P., Matthews T., Muchmore E., Nara P. L., Wei Q., Rimsky L., Weinhold K., Fultz P. N. Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. J. Virol. 69:1995;6239-6248.
19. Hanson C. V. Measuring vaccine-induced HIV neutralization: Report of a workshop. AIDS Res. Hum. Retroviruses. 10:1994;645-648.
20. Hedman K., Rousseau S. A. Measurement of avidity of specific IgG for verification of recent primary rubella. J. Med. Virol. 27:1982;288-292.
21. Hollinger F. B., Brenner J. W., Myers L. E., Gold J. W. M., McQuay L. Standardization of sensitive human immunodeficiency coculture procedures and establishment of a multicenter quality assurance program for the AIDS clinical trials group. J. Clin. Microbiol. 30:1992;1787-1794.
22. Jones D. H., McBride B. W., Roff M. A., Farrar G. H. Efficient purification and rigorous characterization of a recombinant gp120 for HIV vaccine studies. Vaccine. 13:1995;991-999.
23. Moor-Jankowski J., Mahoney C. J. Chimpanzees in captivity: Humane handling and breeding within the confines imposed by medical research and testing. J. Med. Primatol. 18:1989;1-26.
24. Nara P. L., Hatch W. C., Dunlop N. M., Robey W. G., Arthur L. O., Gonda M. A., Fischinger P. J. Simple, rapid, quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody. AIDS Res. Hum. Retroviruses. 3:1987;283-302.
25. Nara P. L., Merges M., Layne S., Tsai W. P., Dunlop N. M. In vitro measurements of neutralizing and cell-fusion inhibiting antibodies directed to HIV. Coligan J. E., Kruisbeek A. M., Marguilies D. H., Schevach E. M., Strober W. Current Protocols in Immunology. 1997;Wiley, New York.
26. Pialoux G., Excler J.-L., Rivière Y., Gonzales-Canali G., Feuillie V., Coulaud P., Gluckman J.-C., Matthews T. J., Meignier B., Kieny M.-P., Gonnet P., Diaz I., Méric C., Paoletti E., Tartaglia J., Salomon H., Plotkin S., AGIS Group ANRS. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN). followed by a recombinant glycoprotein 160 (MN/LAI). AIDS Res. Hum. Retroviruses. 11:1995;373-381.
27. Putkonen P., Thorstensson R., Ghavamzadeh L., Albert J., Hild K., Biberfeld G., Norrby E. Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys. Nature. 352:1991a;436-438.
28. Putkonen P., Thorstensson R., Walther L., Albert J., Akerblom L., Granquist O., Wadell G., Norrby E., Biberfeld G. Vaccine protection against HIV-2 infection in cynomolgus monkeys. AIDS Res. Hum. Retroviruses. 7:1991b;271-277.
29. Saksela K., Muchmore E., Girard M., Fultz P., Baltimore D. High viral load in lymph nodes and latent human immunodeficiency virus (HIV) in peripheral blood cells of HIV-1-infected chimpanzees. J. Virol. 67:1993;7423-7427.
30. Shibata R., Hoggan M. D., Broscius C., Englind G., Theodore T. S., Buckler-White A., Arthur L. O., Israel Z., Schultz A., Lane H. C., Martin M. A. Isolation and characterization of a syncytium-inducing macrophage/T-cell line-tropic human immunodeficiency virus type 1 isolate that readily infects chimpanzee cells in vitro and in vivo. J. Virol. 69:1995;4453-4462.
31. Shibata R., Siemon C., Cho M. W., Arthur L. O., Ngida S. M., Matthews T., Sawyer L. A., Schultz A., Murthy K. K., Israel Z., Javadian A., Frost P., Kennedy R. C., Lane H. C., Martin M. A. Resistance of previously infected chimpanzees to successive challenges with a heterologous intraclade B strain of human immunodeficiency virus type 1. J. Virol. 70:1996;4361-4369.
32. Taylor J., Weinberg R., Tartaglia J., Richardson C., Alkhatib G., Briedis D., Norton E., Paoletti E. Nonreplicating viral vectors as potential vaccines: Recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins. Virology. 187:1992;321-328.
33. Vancott T. C., Polonis V. R., Loomis L. D., Michael N. L., Nara P. L., Birx D. L. Diiferential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. AIDS Res. Hum. Retroviruses. 11:1995;1379-1391.
34. Van Rompay K. K., Otsyula M. G., Tarara R. P., Canfield D. R., Berardi C. J., Chesney M. B., Marthas M. L. Vaccination of pregnant macaques protects newborns against mucosal simian immunodeficiency virus infection. J. Infect. Dis. 173:1996;1327-1335.
35. Vella C., Smith M. H., Farrar G. H., Jones J. H., Daniels R. S. A molecular and serologic study of the envelope gene of the British isolate GB8. Vaccine. 13:1995;735-742.
36. Walker C. M. Priming of cytotoxic T lymphocyte responses with recombinant HIV envelope proteins in murine and primate models. Girard M., Valette L. Retroviruses of Human AIDS and related animal diseases, 8th Colloque des Cent Gardes. 1993;321-325 Fondation Marcel Mérieux, Lyon.
37. Wyand M. S., Manson K. H., Garcia-Moll M., Montefiori D., Desrosiers R. C. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J. Virol. 70:1996;3724-3733.
38. Zolla-Pazner S., Sharpe S. A resting cell assay for improved detection of antibody-mediated neutralization of HIV type 1 primary isolates. AIDS Res. Hum. Retroviruses. 11:1995;1149-1158.
39. S. Zolla-Pazner, M. Robert-Guroff, K. Steimer, R. Natuk, M. Lubeck, J. Eichberg, T. Matthews, R. Gallo, N. Kalyan, S. Xu, F. Sinangil, 1996, Protection of chimpanzees correlates with the presence of neutralizing antibodies to lab strains and primary isolates of HIV-1, 41, Eight Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS, Washington, DC.